首页> 美国卫生研究院文献>New Microbes and New Infections >Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples
【2h】

Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples

机译:人皮德玛氏菌:一种罕见的从人临床样品中分离出来的耐达托霉素的革兰氏阳性菌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

During a 12-year period, Dermabacter hominis was isolated from 21 clinical samples belonging to 14 patients attending a tertiary hospital in León, Spain. Samples included blood cultures (14), peritoneal dialysis catheter exit sites (three), cutaneous abscesses (two), an infected vascular catheter (one) and a wound swab (one). Identification was made by API Coryne™ V2.0, Biolog™ GP2 and 16S rRNA gene amplification. Six febrile patients had positive blood cultures (one, two or three sets) and all of them were treated with teicoplanin (two patients), vancomycin, ampicillin plus gentamicin, amoxicillin/clavulanic acid and ciprofloxacin (one each). An additional patient with a single positive blood culture was not treated, the finding being considered non-significant. In the remaining seven patients the organism was isolated from a single specimen and three of them received antimicrobial treatment (ciprofloxacin, ceftriaxone plus vancomycin and amoxicillin/clavulanic acid). At least ten patients had several underlying diseases and conditions, and no direct mortality was observed in relation to the isolated organism. All isolates were susceptible to vancomycin, rifampin and linezolid. Resistance to other antibiotics varied: erythromycin (100%), clindamycin (78.5%), ciprofloxacin (21.4%) and gentamicin, quinupristin-dalfopristin, benzylpenicillin and imipenem 7.1% each. Thirteen isolates were highly resistant to daptomycin with MICs ranging from 8 to 48 (MIC90 = 32 mg/L); only one was daptomycin-sensitive (MIC = 0.19 mg/L).
机译:在12年的时间里,从西班牙莱昂一家三级医院的14例患者的21份临床样本中分离出人皮德氏杆菌。样本包括血液培养物(14),腹膜透析导管出口位点(三个),皮肤脓肿(两个),被感染的血管导管(一个)和伤口拭子(一个)。通过API Coryne™V2.0,Biolog™GP2和16S rRNA基因扩增进行鉴定。 6例发热患者的血液培养呈阳性(1、2或3组),所有患者均接受替考拉宁(2例),万古霉素,氨苄青霉素加庆大霉素,阿莫西林/克拉维酸和环丙沙星治疗(各1例)。没有对另一名血液培养阳性的患者进行治疗,这一发现被认为是不重要的。在其余的七名患者中,从单个标本中分离出该生物,其中三名接受了抗菌治疗(环丙沙星,头孢曲松钠加万古霉素和阿莫西林/克拉维酸)。至少有十名患者患有几种潜在的疾病和状况,并且与分离出的生物体相比没有观察到直接死亡。所有分离株均对万古霉素,利福平和利奈唑胺敏感。对其他抗生素的耐药性各不相同:红霉素(100%),克林霉素(78.5%),环丙沙星(21.4%)和庆大霉素,奎奴普丁-达福普汀,苄青霉素和亚胺培南各7.1%。十三株对达托霉素具有高度耐药性,MIC范围为8至48(MIC90 = 32 mg / L);只有一种对达托霉素敏感(MIC = 0.19 mg / L)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号